The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has reviewed all available data on the performance of the vaccine in the settings of the variants of concern. In clinical trials this vaccine has been tested against a variety of SARS-CoV-2 virus variants, including B1.351 (first identified in South Africa) and P.2 (first identified in Brazil), and found to be effective.
SAGE currently recommends using this vaccine, according to the WHO Prioritization Roadmap, even if variants of concern are present in a country. As new data becomes available, WHO will update recommendations accordingly.
The available data suggest that COVID-19 Janssen will reduce the risk of severe COVID-19 disease, including in the context of currently identified COVID-19 variants.